Dr Randall on the Clinical Relevance of Comparative Data on Surgical Procedures for Femoral Metastases

“The real challenge, from a structural standpoint, is choosing the right surgical strategy when a patient has either an impending or realized fracture. We want to impart functionality to the patient, minimize complications, and align treatment with the patient's overall prognosis.”

R. Lor Randall, MD, FACS, the David Linn Endowed Chair for Orthopedic Surgery, the chair of the Department of Orthopedic Surgery, and a professor at UC Davis Comprehensive Cancer Center, discussed the clinical rationale for comparing outcomes with intramedullary (IM) nailing and endoprosthetic (EP) reconstruction and why this research is relevant to medical oncologists.

As systemic therapies continue to improve and patients live longer with metastatic disease, the incidence of skeletal-related events is growing, Randall began. The primary challenge from a structural standpoint is selecting the most appropriate surgical strategy when a patient presents with either an impending or realized fracture, he asserted. Randall characterized IM nailing and EP reconstruction as very disparate surgical procedures, emphasizing that the recovery paths for patients are meaningfully different. Accordingly, the surgical decision-making process must prioritize imparting functionality to the patient and minimizing complications while ensuring the treatment remains aligned with the individual’s overall prognosis.

The meta-analysis, which comprised data from over 1,000 patients across multiple studies, was designed to assess meaningful clinical outcomes with IM nailing vs EP reconstruction. These outcomes included infection rates, implant failure, and the necessity for re-operation in those with metastatic disease. Outcomes were evaluated through both a short-term lens of less than 6 months and over a longer period beyond that timeframe, Randall said.

Randall noted that the study was not designed to declare a single "best" approach for all patients. Instead, it serves to clarify the inherent trade-offs between the two strategies, allowing the multidisciplinary care team to make better-informed decisions. Being familiar with these disparate outcomes ensures that the selected treatment path best supports the patient's quality of life during advanced disease, he emphasized. Ultimately, this research is highly relevant to medical oncologists, even though they are not performing the surgeries themselves, Randall concluded.